Patents Examined by Michael P Cohen
  • Partial melt co-crystallization compositions
    Patent number: 11045401
    Abstract: A co-crystallization composition containing erythritol and an active; a method of making the co-crystallization composition; and a method of using the co-crystallization composition are disclosed.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: June 29, 2021
    Assignee: Heartland Consumer Products LLC
    Inventors: Shyhyuan Liao, Joseph R. Panarisi, Steven J. Catani
  • Cannabinoid chewing gum with improved release of cannabinoids
    Patent number: 11013685
    Abstract: A chewing gum for mucosal delivery of cannabinoids, the chewing gum being formulated as an extruded chewing gum including water-soluble chewing gum ingredients mixed into water-insoluble gum base, wherein the gum base includes one or more natural resins in an amount of 10-40% by weight of the gum base, one or more elastomers in an amount of 3-30% by weight of the gum base, and one or more elastomer plasticizers in an amount of 8-50% by weight of the gum base, and wherein the chewing gum includes one or more cannabinoids, and wherein the release rate of the one or more cannabinoids is at least 10% by weight of the one or more cannabinoids within the first 5 minutes upon oral administration.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: May 25, 2021
    Inventors: Heidi Ziegler Bruun, Dorthe Schackinger Boesen, Ane Eriksen
  • Bakuchiol compositions for treatment of post inflammatory hyperpigmentation
    Patent number: 11013699
    Abstract: Methods for treating excess pigmentation, including treatment of post inflammatory hyperpigmentation (PIH), are disclosed. The disclosed methods comprise administration of a composition comprising bakuchiol substantially free of furanocoumarins to a mammal. Compositions comprising bakuchiol and methods for their preparation are also disclosed.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: May 25, 2021
    Assignee: Unigen, Inc.
    Inventors: Mei Feng Hong, Qi Jia, Lidia Alfaro Brownell
  • Gas-encapsulated acoustically responsive stabilized microbubbles and methods for treating cardiovascular disease
    Patent number: 11007284
    Abstract: Acoustically responsive stabilized microbubbles formulated with a phospholipid monolayer shell, an encapsulated bioactive gas, and an encapsulated perfluorocarbon gas of the formula CxFy in a volume ratio of from about 10:1 to about 1:10, wherein X is greater than or equal to 3, are disclosed. Also provided are methods for promoting localized vasodilation in a patient in need thereof by delivering a microbubble comprising a phospholipid monolayer shell and an encapsulated bioactive gas locally to a target diseased section of the patient's vasculature; and releasing the bioactive gas at the target diseased section, wherein the microbubble comprises the bioactive gas in a ratio of from about 10:1 to about 1:10 by volume with a perfluorocarbon gas.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: May 18, 2021
    Assignee: University of Cincinnati
    Inventors: Christy Holland, Himanshu Shekhar, Arunkumar Palaniappan
  • Topical copper ion treatments and methods of treatment using topical copper ion treatments in the oral-respiratory-otic areas of the body
    Patent number: 11007143
    Abstract: Copper ion treatments and methods of treatment are provided to treat various body conditions affecting the oral, respiratory and/or otic areas of the body. The copper ion treatments contain copper ions which bring about local and systemic therapeutic effects as a result of contacting anatomical tissue of the oral cavity, the nasal passages or ear canal. The copper ion treatments and methods involve copper ion-containing solutions, copper ion toothpaste and copper ion mouthwash. The copper ion-containing solutions can be delivered to the oral cavity by spraying or swabbing, can be delivered to the nostrils as spray, drops, or by swabbing, and can be delivered to the ear canal as spray, drops, or by swabbing. The copper ion toothpaste is used for brushing the teeth, and the copper ion mouthwash is used for rinsing the mouth.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 18, 2021
    Assignee: CDA RESEARCH GROUP, INC.
    Inventors: ChunLim Abbott, Dominic C. Abbott
  • Copper ion compositions and methods of treatment for conditions caused by coronavirus and influenza
    Patent number: 11000545
    Abstract: Provided herein are formulations containing copper ions and methods of treating underlying infections and conditions caused by coronavirus, particularly COVID-19, and influenzas, particularly influenza A and/or influenza B using such formulations. Methods of treating the underlying viruses and their resultant conditions using topical copper ion treatments are provided. A topical treatment in its basic form comprises a biocompatible copper ion solution or suspension obtained by leaching of the copper ions from copper metal. The copper ion solution or suspension may be combined with various carriers to form the copper ion treatment including creams or solutions. Methods of making the copper ion solution or suspension from solid copper metal in a biocompatible solution are also provided.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: May 11, 2021
    Assignee: CDA RESEARCH GROUP, INC.
    Inventors: ChunLim Abbott, Dominic C. Abbott
  • Dosage and formulation
    Patent number: 11000517
    Abstract: The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 400 micrograms aclidinium bromide.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: May 11, 2021
    Assignee: Almirall, S.A.
    Inventors: Rosa Lamarca Casado, Gonzalo De Miquel Serra
  • Musk compositions and methods of use thereof
    Patent number: 10988706
    Abstract: A fragrance composition comprising one or more musk or fragrance accords for use in reducing or inhibiting a subject's physiological reaction to stress. The composition can be incorporated into consumer products.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: April 27, 2021
    Assignee: TAKASAGO INTERNATIONAL CORPORATION
    Inventors: Raphael K. L. Kang, Alba T. Cilia
  • Mixtures containing (E)-3-benzo[1,3]dioxol-5-yl-N,N-diphenyl-2-propenamide
    Patent number: 10980727
    Abstract: Mixtures comprising a selected cooling active ingredient (E)-3-benzo[1,3]dioxol-5-yl-N,N-diphenyl-2-propenamide and at least one other substance which acts as a solvent for (E)-3-benzo[1,3]dioxol-5-yl-N,N-diphenyl-2-propenamide, wherein the substance is selected form the group consisting of benzyl benzoate, diethyl succinate, triethyl citrate, triacetin, ethanol, peppermint oil, anethol, optamint, propylene glycol, further cooling active ingredients or mixtures thereof.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: April 20, 2021
    Assignee: SYMRISE AG
    Inventors: Benoit Join, Michael Backes, Arnold Machinek, Ulrike Simchen, Jenny Weissbrodt, Jens Fahle
  • Bactericidal and virucidal pharmaceutical composition
    Patent number: 10973787
    Abstract: A bactericidal and virucidal pharmaceutical composition for use on epithelial tissues such as pulmonary, nasal and oral tissues, which comprises a non-steroidal anti-inflammatory drug (NSAID) in a concentration between 5 and 500 mM and a salt, being the NSAID preferably solubilized in a hypertonic saline solution applicable in therapies for viral infections of the Herpes simplex type. The composition can be used in therapies for herpes simplex viral infections, be used as a bactericidal mouthwash, or be vehiculated to the lung by using a nebuliser, for cystic fibrosis.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: April 13, 2021
    Assignee: Quimica Luar SRL
    Inventors: Luis Alberto Argañarás, Adrian Javier Muñoz, Roxana Valeria Alasino, Ariel Gustavo Garro, Dante Miguel Beltramo
  • Collagen matrix or granulate blend of bone substitute material
    Patent number: 10960107
    Abstract: A collagen matrix, granulate blend, and process for making and using a collagen matrix or granulate blend including collagen and particles or granules of a biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material comprising a sintered CAP core and a closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, wherein the closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core has a homogeneous coarse external surface comprising flat crystal platelets.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: March 30, 2021
    Assignee: Geistlich Pharma AG
    Inventors: Claudio Zihlmann, Michael Bufler
  • Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva
    Patent number: 10960075
    Abstract: A composition includes an oral thin film pharmaceutical dosage form configured to disintegrate in saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein. The dosage form includes a therapeutically effective amount of melatonin in a polymer carrier matrix and a sufficient amount of acid to impart the pH to the saliva. The dosage can completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: March 30, 2021
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Particulate materials
    Patent number: 10945972
    Abstract: The present invention relates to active substances in particulate form, to methods for preparing them and to their uses. The present invention provides particulate powders, such as might be of use for delivery using a dry powder inhaler (DPI) or similar delivery device, having properties which may be beneficial to the DPI delivery process.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: March 16, 2021
    Assignee: Nektar Therapeutics
    Inventors: Peter York, Boris Yu Shekunov, Mahboob Ur Rehman, Jane Catherine Feeley
  • Tableted cannabinoid chewing gum with polyvinyl acetate elastomer plasticizers
    Patent number: 10933017
    Abstract: The present invention relates to a tableted chewing gum composition for oral administration of cannabinoids, the composition comprising water-soluble chewing gum ingredients and water-insoluble gum base located in a plurality of particles, wherein a first population of particles comprises water-insoluble gum base, including one or more polyvinyl acetate elastomer plasticizers, and a second population of particles comprises water-soluble chewing gum ingredients, the second population of particles being free of water-insoluble gum base, wherein the chewing gum composition comprises one or more cannabinoids.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: March 2, 2021
    Assignee: NORDICCAN A/S
    Inventors: Heidi Ziegler Bruun, Dorthe Schackinger Boesen, Ane Eriksen
  • Hemostatic devices and methods of use
    Patent number: 10933174
    Abstract: An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a substrate having a hemostatic agent and an active pharmaceutical ingredient selectively positioned on the substrate. Kits, systems and methods are disclosed.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: March 2, 2021
    Assignee: MEDTRONIC, INC.
    Inventors: Satish Pulapura, Fatima Buevich, Jorie S. Soskin, Franklin R. Mansfield, Kai R. Worrell, Charlie Wood, Jorge Alberto Trevino Blanco
  • Compositions for treatment of attention deficit hyperactivity disorder
    Patent number: 10905652
    Abstract: Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: February 2, 2021
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Polyphenol-reactive oxygen species compositions and methods
    Patent number: 10894031
    Abstract: Disclosed herein are nutraceutical compositions comprising or consisting essentially of one or more types of polyphenols (e.g., a green tea polyphenol) and one or more types of reactive oxygen species, and methods for their use to treat gastrointestinal conditions, inflammatory conditions, and immune conditions.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: January 19, 2021
    Assignee: PowerGut, INC.
    Inventors: Michael Evans, Robert Wotring
  • Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
    Patent number: 10888522
    Abstract: Controlled-release therapeutic compositions including melatonin combined with sedative and/or analgesic ingredients are described. The compositions have a solid core including melatonin in an acidified polymeric matrix. A sedative ingredient such as GABA receptor agonist may also be in the acidified polymeric matrix. The composition may include an expedited release portion providing a burst release of active ingredients and a sustained release portion providing a sustained release of active ingredients.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: January 12, 2021
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Daniel Hassan, Christopher Diorio, Fred Hassan
  • Compositions for treatment of attention deficit hyperactivity disorder
    Patent number: 10881618
    Abstract: Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: January 5, 2021
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • 2,3,6-trimethylcyclohexanol as a scenting and/or flavoring agent
    Patent number: 10876068
    Abstract: The present invention primarily concerns the use of 2,3,6-trimethylcyclohexanol as a fragrance and/or flavoring. The invention also concerns new fragrance and/or flavoring compositions comprising 2,3,6-trimethylcyclohexanol and their use, perfumed and/or flavored articles comprising 2,3,6-trimethylcyclohexanol and various methods for imparting, modifying and/or enhancing certain scent and/or flavor notes.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: December 29, 2020
    Assignee: SYMRISE AG
    Inventors: Bernd Hölscher, Manfred Meier